Nonalcoholic fatty liver disease and hepatocellular carcinoma

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Kikuchi, Luciana ^a   Oliveira, Cláudia P ^a   Carrilho, Flair J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CELL PROLIFERATION; DIABETES MELLITUS; DYSLIPIDEMIA; FOLLOW UP; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; REVIEW; TISSUE MICROARRAY; TRANSCRIPTION INITIATION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; LIVER NEOPLASMS; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84897515027     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/106247     Document Type: Review

References (37)

1. Parkin D. M., Bray F., Ferlay J., Pisani P., Estimating the world cancer burden: Globocan 2000. International Journal of Cancer 2001 94 2 153 156 2-s2.0-0035888074 10.1002/ijc.1440 (Pubitemid 32911406)
2. El-Serag H. B., Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004 127 5, supplement 1 S27 S34 2-s2.0-7044231396 10.1053/j.gastro.2004.09.013 (Pubitemid 39423367)
3. Bruix J., Sherman M., Management of hepatocellular carcinoma. Hepatology 2005 42 5 1208 1236 2-s2.0-28844480321 10.1002/hep.20933 (Pubitemid 43112690)
4. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., Musso A., de Paolis P., Capussotti L., Salizzoni M., Rizzetto M., Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002 123 1 134 140 2-s2.0-0036302288 10.1053/gast.2002.34168 (Pubitemid 34747534)
5. McCullough A. J., The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clinics in Liver Disease 2004 8 3 521 533 2-s2.0-4344628555 10.1016/j.cld.2004.04.004 (Pubitemid 39141140)
6. Marrero J. A., Fontana R. J., Su G. L., Conjeevaram H. S., Emick D. M., Lok A. S., NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002 36 6 1349 1354 2-s2.0-0036894480 10.1053/jhep.2002.36939 (Pubitemid 35403524)
7. Bugianesi E., Non-alcoholic steatohepatitis and cancer. Clinics in Liver Disease 2007 11 1 191 207 2-s2.0-34249699540 10.1016/j.cld.2007.02.006 (Pubitemid 46829971)
8. Chagas A. L., Kikuchi L. O. O., Oliveira C. P. M. S., Vezozzo D. C. P., Mello E. S., Oliveira A. C., Cella L. C., Herman P., Bachella T., Caldwell S. H., Alves V. A. F., Carrilho F. J., Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Brazilian Journal of Medical and Biological Research 2009 42 10 958 962 2-s2.0-71049127867 10.1590/S0100-879X2009005000019
9. Harrison S. A., Torgerson S., Hayashi P. H., The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. The American Journal of Gastroenterology 2003 98 9 2042 2047 2-s2.0-0141510580 10.1111/j.1572-0241.2003.07659.x (Pubitemid 37185803)
10. Adams L. A., Lymp J. F., St. Sauver J., Sanderson S. O., Lindor K. D., Feldstein A., Angulo P., The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005 129 1 113 121 2-s2.0-22344452893 10.1053/j.gastro.2005.04.014 (Pubitemid 41002048)
11. Hashimoto E., Yatsuji S., Tobari M., Taniai M., Torii N., Tokushige K., Shiratori K., Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Journal of Gastroenterology 2009 44 19 89 95 2-s2.0-58849090967 10.1007/s00535-008-2262-x
12. Ascha M. S., Hanouneh I. A., Lopez R., Tamimi T. A.-R., Feldstein A. F., Zein N. N., The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010 51 6 1972 1978 2-s2.0-77952730428 10.1002/hep.23527
13. Kodama K., Tokushige K., Hashimoto E., Taniai M., Shiratori K., Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. Alcoholism 2013 37 supplement 1 E247 E252 10.1111/j.1530-0277.2012.01900.x
14. Calle E. E., Rodriguez C., Walker-Thurmond K., Thun M. J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England Journal of Medicine 2003 348 17 1625 1638 2-s2.0-0037464510 10.1056/NEJMoa021423 (Pubitemid 36459468)
15. Nair S., Mason A., Eason J., Loss G., Perrillo R. P., Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002 36 1 150 155 2-s2.0-0036288123 10.1053/jhep.2002.33713 (Pubitemid 34700772)
16. Wideroff L., Gridley G., Mellemkjaer L., Chow W.-H., Linet M., Keehn S., Borch-Johnsen K., Olsen J. H., Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. Journal of the National Cancer Institute 1997 89 18 1360 1365 2-s2.0-0030774675 (Pubitemid 27418027)
17. Davila J. A., Morgan R. O., Shaib Y., McGlynn K. A., El-Serag H. B., Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005 54 4 533 539 2-s2.0-15544382574 10.1136/gut.2004.052167 (Pubitemid 40403031)
18. El-Serag H. B., Tran T., Everhart J. E., Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004 126 2 460 468 2-s2.0-0842321807 10.1053/j.gastro.2003.10.065 (Pubitemid 38182303)
19. World Health Organization, Obesity epidemic puts millions at risk for related diseases [press release WHO/46]. http://www.who.int/archives/inf-pr- 1997/en/pr97-46.html
20. IARC, IARC Handbooks of Cancer Prevention. Weight Control and Physical Activity 2002 Lyon, France International Agency for Research on Cancer
21. Mokdad A. H., Ford E. S., Bowman B. A., Dietz W. H., Vinicor F., Bales V. S., Marks J. S., Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Journal of the American Medical Association 2003 289 1 76 79 2-s2.0-0037223174 10.1001/jama.289.1.76 (Pubitemid 36026281)
22. Canman C. E., Kastan M. B., Induction of apoptosis by tumor suppressor genes and oncogenes. Seminars in Cancer Biology 1995 6 1 17 25 2-s2.0-0029248011
23. Leclerq I. A., Farrell G. C., Leptin is required for the development of hepatic fibrosis. Hepatology 2000 32, article 302A
24. Yang S. Q., Lin H. Z., Hwang J., Chacko V. P., Diehl A. M., Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Research 2001 61 13 5016 5023 2-s2.0-0035392939 (Pubitemid 32681529)
25. Pitot H. C., Pathways of progression in hepatocarcinogenesis. The Lancet 2001 358 9285 859 860 2-s2.0-0035883904 10.1016/S0140-6736(01)06038-X (Pubitemid 32900565)
26. Kahn C. R., White M. F., de Groot L. J., Molecular mechanisms of insulin action. Endocrinology 1995 Philadelphia, Pa, USA Saunders 1373 1388
27. Zumoff B., Hormonal abnormalities in obesity. Acta Medica Scandinavica 1988 223 723 153 160 2-s2.0-0023758743
28. Kim H., Park C., Han K.-H., Choi J., Kim Y. B., Kim J. K., Park Y. N., Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. Journal of Hepatology 2004 40 2 298 304 2-s2.0-1642532389 10.1016/j.jhep.2003. 10.023 (Pubitemid 38115836)
29. Roskams T., Yang S. Q., Koteish A., Durnez A., DeVos R., Huang X., Achten R., Verslype C., Diehl A. M., Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease. American Journal of Pathology 2003 163 4 1301 1311 2-s2.0-0042033294 (Pubitemid 37175079)
30. Kasai H., Okada Y., Nishimura S., Rao M. S., Reddy J. K., Formation of 8-hydroxydeoxyguanosine in liver DNA of rats following long-term exposure to a peroxisome proliferator. Cancer Research 1989 49 10 2603 2605 2-s2.0-0024323931 (Pubitemid 19143385)
31. Hu W., Feng Z., Eveleigh J., Iyer G., Pan J., Amin S., Chung F.-L., Tang M.-S., The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis 2002 23 11 1781 1789 2-s2.0-0036850924 (Pubitemid 35355927)
32. Stefano J. T., de Oliveira C. P., Corrêa-Giannella M. L., Soares I. C., Kubrusly M. S., Bellodi-Privato M., de Mello E. S., de Lima V. M. R., Carrilho F. J., Alves V. A. F., Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression? Liver International 2011 31 3 377 385 2-s2.0-79551543208 10.1111/j.1478-3231.2010. 02370.x
33. Kubrusly M. S., Corrêa-Giannella M. L., Bellodi-Privato M., de Sá S. V., de Oliveira S. C. P. M., Soares I. C., Wakamatsu A., Alves V. A. F., Giannella-Neto D., Bacchella T., Machado M. C. C., D'Albuquerque L. A. C., A role for mammalian target of rapamycin (mTOR) pathway in non alcoholic steatohepatitis related-cirrhosis. Histology and Histopathology 2010 25 9 1123 1131 2-s2.0-77957336340
34. Sato W., Horie Y., Kataoka E., Ohshima S., Dohmen T., Iizuka M., Sasaki J., Sasaki T., Hamada K., Kishimoto H., Suzuki A., Watanabe S., Hepatic gene expression in hepatocyte-specific Pten deficient mice showing steatohepatitis without ethanol challenge. Hepatology Research 2006 34 4 256 265 2-s2.0-33645025771 10.1016/j.hepres.2006.01.003
35. Li X., Zhou X.-P., Guan Y.-S., Wang Y.-X. J., Magnetic resonance imaging of hepatocellular carcinoma induced by diethylnitrosamine in Sprague-Dawley rats. Hepatobiliary & Pancreatic Diseases International 2005 4 3 427 434 2-s2.0-23944436009
36. de Lima V. M., Oliveira C. P., Alves V. A., Chammas M. C., Oliveira E. P., Stefano J. T., de Mello E. S., Cerri G. G., Carrilho F. J., Caldwell S. H., A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. Journal of Hepatology 2008 49 6 1055 1061 2-s2.0-55749106570 10.1016/j.jhep.2008.07.024
37. Hoshida Y., Fuchs B. C., Tanabe K. K., Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. Current Cancer Drug Targets 2012 12 9 1129 1159 10.2174/15680096112091129